NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...
If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder. Not eligible? Contact the stakeholder organisation that most closely represents your interests and ...
If you're developing a healthtech product, understanding NICE's priorities is crucial. For 2024/25, NICE is focussing on innovations addressing: ...
Dear stakeholders, For information, the company have advised that they are no longer pursuing a Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Draft guidance published for an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.
Final guidance published today recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma when ...